Coronavirus (COVID-19) was officially declared a pandemic by the World Health Organization on 12 March 2020. As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to this outbreak.
The ABPI is working to ensure that the UK has the best relationship with the EU for patients, public health and the life sciences sector.
In August 2017, the Life Sciences Industrial Strategy was published – a report to Government from the Life Sciences sector, including the ABPI.
Medicines are transforming our lives like never before. We want the UK to be the best place in the world to research, develop and use the medicines of the future.
The UK has a long-standing reputation for world-leading research into life sciences and medicine. Recent development in basic science means we understand diseases better than ever before.
A quarter of a million people are employed in the UK’s life science sector today. We need a continuous supply of specialists to stay competitive, meet the demands of an evolving, technology-based world and pioneer the next wave of medicines and vaccines.
The UK has a long-standing reputation for research into medicine and advances in basic science mean we understand diseases better than we've ever done before.
Clinical trials are very important for finding out whether a medicine works and is safe. Every medicine used in the NHS has to be tested in a clinical trial before its used.
Clinical trials are essential for testing whether a medicine is safe and effective, but really its only the first step. They need to be monitored and regulated for their whole lifetime.
The way we look for new treatments and cures is evolving, and medicines are more personalised now than ever before. Treatments are becoming more sophisticated as we gain a better understanding of science and disease.